Immediate Postpartum Glucose Tolerance Testing
Launched by MEMORIALCARE HEALTH SYSTEM · Dec 12, 2019
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how well a glucose tolerance test, done right after giving birth, can help in managing gestational diabetes. Typically, women with gestational diabetes have a glucose test about six weeks after they give birth to check their blood sugar levels. This study aims to see if doing the test during the hospital stay after delivery is more accurate and encourages more women to get tested.
To participate, women need to be at least 18 years old, have been pregnant for at least 34 weeks, and have been diagnosed with A1 or A2 gestational diabetes. They should be either pregnant or just had their baby. If someone has certain medical conditions or has used steroids recently, they may not be eligible. Participants will take the glucose test while still in the hospital, and the goal is to find out if this approach leads to better testing and monitoring for those who had gestational diabetes.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Pregnant or recently postpartum (postpartum day 0 or 1)
- • ≥ 18 years of age
- • Gestational age ≥34 weeks
- • A1 or A2 gestational diabetes
- Exclusion Criteria:
- • Medical exclusion from completing glucose tolerance testing
- • Steroid administration within 10 days prior to enrollment
- • Chronic steroid use
About Memorialcare Health System
MemorialCare Health System is a prominent integrated healthcare organization based in Southern California, dedicated to providing high-quality, patient-centered care across a diverse range of medical services. With a strong commitment to clinical excellence, MemorialCare conducts innovative clinical trials that advance medical research and improve treatment outcomes. The organization operates several leading hospitals, outpatient facilities, and specialized care centers, leveraging cutting-edge technology and a collaborative approach to enhance the health and well-being of the communities it serves. MemorialCare's focus on research and development underscores its mission to deliver breakthrough therapies and foster advancements in healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Long Beach, California, United States
Patients applied
Trial Officials
Kenneth Chan, MD
Principal Investigator
Magella Medical Group
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials